TGFB2
Transforming growth factor beta-2 proprotein
As of the edition of 20 October 2026, TGFB2 (transforming growth factor beta-2 proprotein, UniProt P61812) has 6 drugs tested at it and 8 companies on the list, 5 on route A and 1 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P61812
- How well studied
- Biology documented; no tool compounds or approved drug yet
- Where it sits in the cell
- Secreted
- Solved structures
- 11
- Disease areas
- Cancer; Blood and lymph; Inherited and neonatal; Lungs and airways; Urinary and reproductive; Digestive system; Pregnancy and women's health; Skin and connective tissue
- Registered trials of its drugs
- 140
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Went quiet | 2 |
| Stopped | 3 |
| Total | 6 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Luspatercept | Marketed | Phase 4 | Ends 2031 |
| Bintrafusp alfa | Stopped | Phase 3 | none listed |
| Fresolimumab | Stopped | Phase 2 | none listed |
| Trabedersen | Stopped | Phase 3 | none listed |
| AP 12009 | Went quiet | Phase 1 | none listed |
| OT-101 | Went quiet | Phase 3 | none listed |
6 of 6 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 5 |
| Route B | 1 |
| Engaged | 2 |
| Total on the list | 8 |
| Company | Route |
|---|---|
| Bristol Myers Squibb | Route B |
| Oncotelic | Route A |
| Ocumension | Route A |
The other 5 companies at TGFB2
In the product8 companies in all; 5 are not named here, and no score is.
See the 8 companies at TGFB2, ranked, with the facts behind eachRequest access. Nothing is shown until you do.